EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS THERAPY IN DIFFERENT POPULATIONS
Main Article Content
Authors
A.N. Iskakova
Al-Farabi Kazakh National University, 71, al-Farabi ave., Almaty 050040, Kazakhstan
E.V. Zholdybayeva
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
Abstract
Introduction. Different drug classes in addition to lifestyle adjustments are used to reduce glucose level. Class of dipeptidyl peptidase-4(DPP4) inhibitors is one of them.
The aim of our study was to compare the glucose-lowering efficacy of DPP4 inhibitors among different populations.
Methods. MEDLINE database has been searched. Randomized controlled trials were included in the analysis if there were comparison of DPP4 inhibitors vs. placebo in a form of monotherapy or combination therapy with treatment duration of at least 12 weeks. Other criteria were information on ethnicity, baseline glycated hemoglobin (HbA1c) levels, fasting plasma glucose (FPG) levels and its levels after therapy, or HbA1c and FPG data compared to the baseline.
Results. Of the 527 publications identified from the databases, 22 studies were included in the analysis. The difference between "Japan", "China", "Korea" and "Europe" subgroups was -0.84% (95% CI -1.07, -0.62; I2 = 65.2%) which was statistically significant (p<0.05). The FPG value difference between the subgroups was -1.07 mmol/L (95% CI -1.26, -0.87; I2 = 83.6%) with a statistically significant probability (p <0.05).
Conclusion. HbA1c-lowering efficacy of DPP4 inhibitors is higher in the Japanese population than in Korean, while FPG-lowering efficacy higher in the Korean population when compared to the Japanese and Chinese populations.
Keywords
meta-analysis, DPP4 inhibitors, gliptins, HbA1c, FPG, type 2 diabetes
Article Details
References
Anciferov M.B., Zilov A.B. Perspektivy primeneniya ingibitorov dipeptidilpeptidazy-4 pri sakharnom diabete tipa 2: iniciaciya I prodolzheniye terapii [Perspectives of applying dipeptidyl peptidase-4 inhibitors in patients with diabetes mellitus type 2: the initiation and continuation of treatment]. Farmateka - Pharmateca, 2010, no. 16.
Gosudarstvennyi reestr lekarstvennyh sredstv, izdelii medicinskogo naznacheniya i medicinskoi tehniki (Public register of medicines, medical devices and medical equipment) Available at:URL (assessed 28 April 2016).
Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.PLoS Med., 2009,vol. 6, no. 7, pp. e1000097.20171303.
The Cochrane Collaboration: Review Manager (RevMan) 5.3 (2014). Available at: URL 13 June 2014).
Kashiwagi A., Kadowaki T., Tajima N. et al. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.Journal of Diabetes Investigation, 2011,vol. 2, no. 5,pp. 381-390. 24843518.
Nonaka K., Kakikawa T., Sato A.et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.Diabetes research and clinical practice, 2008, vol. 79,pp. 291-298.17933414.
Iwamoto Y., Taniguchi T., Nonaka K. et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocrine Journal, 2010,vol. 57, no. 5, pp. 383-394.20332588.
Yang H.K., Min K.W., Park S.W. et al. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.Endocrine Journal, 2015,vol. 62, no. 5,pp. 449-462.25819061.
Kaku K., Itayasu T., Hiroi S., Hirayama M., Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes, Obesity and Metabolism, 2011,vol. 13,pp. 1028-1035.21682833.
Kikuchi M., Haneda M., Koya D. et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.Diabetes research and clinical practice, 2010,vol. 89,pp. 216-223.20537746.
Mohan V., Yang W., Son H-Y. et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.Diabetes research and clinical practice, 2009,vol. 83,pp. 106-116.19097665.
Yang W., Xing X., Lv X. et al. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.J Diabetes, 2015, vol. 7, no. 2,pp. 174-181.24823599.
Seino Y., Fujita T., Hiroi S., Hirayama M., Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.Current Medical Research & Opinion, 2011, vol. 27, no. 3,pp. 21-29.22106975.
Seino Y., Fujita T., Hiroi S., Hirayama M., Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.Current Medical Research & Opinion, 2011,vol. 27, no. 9,pp. 1781-1792. 21806314.
Derosa G., Carbone A., D’Angelo A. et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and b-cell function.Expert Opin. Pharmacother., 2012,vol. 13, no. 17,pp. 2433-2442.23061989.
Derosa G., Ragonesi P.D., Carbone A. et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.Expert Opin. Pharmacother., 2012, vol. 13, no. 18,pp. 2581-2591.23121473.
Derosa G., Ragonesi P.D., Fogaria E. et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.Fundamental & Clinical Pharmacology, 2012,vol. 28, no. 2,pp. 221-229.23039403.
Pan C., Xing X., Han P. et al. Institution Investigators. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism, 2012,vol. 14, no. 8,pp. 737-745.22369287.
Jung C.H., Park C.Y., Ahn K.J. et al. A randomized, double-blind, placebo-controlled,phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.Diabetes Metab Res Rev., 2015, vol. 31, pp. 295-306.25362864.
Van Raalte D.H., van Genugten R.E., Eliasson B. et al. The effect of alogliptin and pioglitazonecombination therapy on various aspects of b-cell function in patients with recent-onset type 2 diabetes. European Journal of Endocrinology, 2014,vol. 170,pp. 565-574.24421302.
Kim M.K., Rhee E., Han K.A. et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.Diabetes Obes Metab, 2015,vol.17, no. 3, pp. 309-312.25475929.
Kaku K., Mori M., Kanoo T., Katou M., Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.Expert Opin. Pharmacother., 2014, vol. 15, no. 15, pp. 2121-2130.25190226.
Inagaki N., Onouchi H., Maezawa H., Kuroda S., Kaku K. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol., 2015,vol. 3, no. 3,pp. 191-197.25609193.
Kadowaki T., Kondo K. Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism, 2013,vol. 15, no.9,pp. 810-818.23464664.
Kadowaki T., Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.Diabetes, Obesity and Metabolism, 2014,vol. 16,pp. 418-425.24205974.
Yang W., Guan Y., Shentu Y. et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.Journal of Diabetes, 2012, vol. 4,pp. 227-237.22672586.
Yang W., Pan C.Y., Tou C., Zhao J., Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial.Diabetesresearch and clinical practice, 2011,vol. 94,pp. 217-224.21871686.
Park H., Park C., Kim Y., Rascati K.L. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis.The Annals of Pharmacotherapy, 2012, vol. 46, pp. 1453-1469.23136353.
Kim Y.G., Hahn S., Oh T.J. et al. Differences in the glucose-liwering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review andmeta-analysis.Diabetalogia, 2013,vol. 56,pp. 696-708.23344728.